KS

Kresten Skak

Vice President, Head Of In Vitro And In Vivo Research at Nykode

Kresten Skak has a diverse range of work experience in the pharmaceutical and biotech industry. Kresten is currently working at Nykode Therapeutics as the Vice President and Head of in vitro and in vivo discovery. Prior to that, they were at Dragonfly Therapeutics CPH, where they started as the Senior Director of Inflammation and later took over as the head of the biology team. During their time at Dragonfly, they built labs from scratch, established biology assays, and developed in vivo models for autoimmune diseases.

Before joining Dragonfly, Kresten Skak worked at LEO Pharma as a Clinical Pharmacologist, responsible for biomarker selection, planning, and execution in clinical trials for dermatology. Kresten also held roles as the Actinic Keratosis Disease Lead and Head of Department, overseeing skin cancer biology research and providing scientific guidance to discovery projects. As the Senior Scientist and Head of Section, they managed the Actinic Keratosis Section and was responsible for animal models and LEO's core facility in histology and flow cytometry.

Earlier in their career, Kresten Skak was a Principal Scientist at Novo Nordisk, where they sourced and evaluated new project opportunities in inflammation. Kresten also worked as a Senior Scientist, coordinating an oncology project and overseeing in vivo cancer models. Kresten had oversight of laboratory technicians and students.

Kresten Skak's work experience also includes being a Senior Visiting Fellow at Peter MacCallum Cancer Centre and a Post Doc and Ph.D. student at Hagedorn Research Institute and The Scripps Research Institute, respectively.

Overall, Kresten Skak has extensive experience in various research, managerial, and leadership roles in the pharmaceutical and biotech industry, with a focus on inflammation, dermatology, and oncology.

Kresten Skak obtained a Master of Science (M.Sc.) degree in Biochemistry from Københavns Universitet - University of Copenhagen from 1990 to 1996. Later, from 1998 to 2001, they pursued a Ph.D. in Immunology from the same institution.

Links